Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

Phase 2

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: MIRAPEX® - low
Drug: MIRAPEX® - medium
Drug: MIRAPEX® - high

Registration Number: NCT02231918

Lead Sponsor: Boehringer Ingelheim

Brief Summary: Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 26

Inclusion Criteria

Male or female patients ages 6 years to 16 years (two age groups, 6 to 11 years and 12 to 16 years, with the same number of patients if possible)
Diagnosis of idiopathic Restless Legs Syndrome (RLS) according to the Clinical RLS criteria of the International Restless Legs Syndrome Study Group (IRLSSG)

All 4 of the following criteria must be present:
- An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs.)
- The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
- The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
- The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present.)
Must meet all 4 of the diagnostic criteria for adult RLS (see inclusion criterion No. 2 above) and either:
1. The child must be able to describe the leg discomfort in their own words or
2. The child must have 2 or 3 of the following:
  - Sleep disturbance
  - Periodic Limb Movements During Sleep (PLMS) index >5 per hour of sleep, or
  - A biological parent or sibling with definite RLS
Written informed consent consistent with International Conference on Harmonisation (ICH)/ Good Clinical Practice (GCP) and Local Institutional Review Board requirements for children obtained prior to any study procedures being performed
Ability and willingness to comply with the study treatment regimen and to attend study assessments
Must be on PPX treatment at the same evening maintenance dose for a minimum of 7 days prior to entry into this study as determined by the investigator
A patient who is taking PPX but not as an evening maintenance dose may return for a repeat screening if the patient can be successfully switched and re-stabilized to an evening PPX maintenance dose

Exclusion criteria:

Any women of childbearing potential having a positive serum pregnancy test at screening
Any women of childbearing potential not using a medically accepted method of contraceptive (Intra-Uterine Device, oral, implantable, injectable contraceptives and estrogen patch, double barrier method [spermicide + diaphragm], or abstinence at the discretion of the investigator)
Patients who have a clinically significant renal disease or serum creatinine level greater than 1.0 mg/dL at screening
Any of the following lab results at screening:
- Hemoglobin (Hgb) below the lower limit of normal (LLN), which is determined to be clinically significant
- Basal thyroid stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significantly (at the investigator's discretion) out of the normal range at screening (if not caused by substitution therapy according to the investigator's opinion)
- Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigator's discretion
Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, pulmonary disease (such as severe asthma) which in the opinion of the investigator would preclude the patient from participating in this study
History or clinical signs of any neurological disease with potential to secondarily cause RLS symptoms
Presence of any other sleep disorder such as Rapid Eye Movement (REM) sleep behavior disorder, narcolepsy, or sleep apnea syndrome
History of schizophrenia or any psychotic disorder, history of mental disorders, or any present Axis I psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) requiring any medical therapy
History of/or clinical signs of epilepsy or seizures other than fever-related seizures in early childhood
History of/or clinical signs of any malignant neoplasm including suspicious undiagnosed skin lesions (which may be melanoma), melanoma, or a history of melanoma
Any other conditions that, in the opinion of the investigator, would interfere with the evaluation of the results or constitute a health hazard for the patient
Allergic response to PPX or the inactive ingredients in its tablet formulation
Had previous treatment with dopamine agonists other than PPX within 14 days prior to the baseline visit
Had any other medical treatment for RLS besides the study medication within 14 days prior to the baseline visit
Had withdrawal symptoms of any medication at screening or at the baseline visit

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MIRAPEX® - low	MIRAPEX® - low	-
MIRAPEX® - medium	MIRAPEX® - medium	-
MIRAPEX® - high	MIRAPEX® - high	-

Primary Outcome Measures

Name	Time	Method
Cmax,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Maximum concentration of the Pramipexole (PPX) in plasma at steady state over a uniform dosing interval (Cmax,ss).
Cmin,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval (Cmin,ss).
Cpre,N	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N (Cpre,N).
Cavg	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Average concentration of the analyte in plasma at steady state (Cavg).
Tmax,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Time from dosing to maximum concentration at steady state (Tmax,ss).
Tmin,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Time from dosing to minimum concentration at steady state (Tmin,ss ).
AUCτ,ss	0.25h before the drug administration on day 1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on Day 1.	Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval (AUCτ,ss ).
λz,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Terminal rate constant in plasma at steady state (λz,ss ).
t1/2,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Terminal half-life of the analyte in plasma at steady state (t1/2,ss ).
MRTpo,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Mean residence time of the analyte in the body at steady state (MRTpo,ss).
CL/F,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Apparent clearance of the analyte in the plasma after extravascular administration at steady state; F = absolute bioavailability factor (CL/F,ss ).
Vz/F,ss	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state (Vz/F,ss ).
Ae 0-12,ss	12 hours after last study drug administration on day 1	Amount of analyte that is eliminated in urine at steady state over a time interval t1to t2 (0-12h).
fe 0-12,ss	12 hours after last study drug administration on day 1.	Fraction of administered drug excreted unchanged in urine at steady state over a time interval t1 to t2 (fe 0-12,ss ).
CLR,ss	12h after last study drug administration on day 1	Renal clearance of the analyte at steady state (CLR(0-12),ss ).
PTF	0.25h before the drug administration on day1 and 0.5 h, 1 h, 2 h, 3 h, 5 h, 7h, 12h and 24h after the last drug administration on day 1.	Peak-trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state.

Secondary Outcome Measures

Name	Time	Method
Number of Patients With Drug Related Adverse Events	From first drug administration until 24 hours after last study drug administration, upto 48 days	Number of patients with adverse events due to study drug.
Vital Signs (Systolic and Diastolic Blood Pressure)	-0:15h(hours) pre-dose, and 0:30h, 1:00h, 2:00h, 3:00h, 5:00h, 7:00h, 12:00h, 24:00h post-dose.	Vital signs (Systolic and diastolic blood pressure (both supine and after standing for 1 minute)).
Vital Signs (Pulse Rate)	-0:15h(hours) pre-dose, and 0:30h, 1:00h, 2:00h, 3:00h, 5:00h, 7:00h, 12:00h, 24:00h	Vital signs (Pulse rate (both supine and after standing for 1 minute)).